Last reviewed · How we verify
5% Albumin infusion 3 hours
5% Albumin infusion works by increasing intravascular volume and maintaining oncotic pressure, thereby improving blood flow and tissue perfusion.
5% Albumin infusion is a plasma protein solution used primarily for volume expansion and maintenance of oncotic pressure in various clinical settings. It is administered over a period of 3 hours and is particularly useful in treating hypovolemia, hypoalbuminemia, and as a supportive therapy in critical care. The product is manufactured by Region Skane and does not have an FDA label, indicating it may be used under specific regional or hospital guidelines. Despite the lack of FDA approval, it is widely recognized for its role in stabilizing patients with fluid and protein deficiencies. The safety profile of 5% Albumin is generally favorable, but it can cause adverse reactions, which are typically mild to moderate.
At a glance
| Generic name | 5% Albumin infusion 3 hours |
|---|---|
| Sponsor | Region Skane |
| Drug class | Plasma expanders |
| Target | Intravascular volume and oncotic pressure |
| Modality | Small molecule |
| Therapeutic area | Hematology |
| Phase | FDA-approved |
Mechanism of action
Albumin is the most abundant protein in human plasma and plays a crucial role in maintaining the colloidal osmotic pressure of blood. By increasing the concentration of albumin in the bloodstream, the infusion helps to draw fluid from the interstitial space into the vascular compartment, effectively expanding blood volume.
Approved indications
Common side effects
- Fever
- Chills
- Nausea
- Headache
- Rash
Key clinical trials
- A Study of Reduced Radiation Therapy and Standard-of-Care Chemotherapy in People With HPV-Positive Throat Cancer (PHASE2)
- Carboplatin, Nab-Paclitaxel, Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell Carcinoma (PHASE2)
- Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors (PHASE1, PHASE2)
- A Prospective, Multicenter, Phase Ib/II Trial of Ivonescimab (AK112) Combined With Albumin-Paclitaxel and Cisplatin as Neoadjuvant Therapy for ESCC (PHASE1, PHASE2)
- A Study in Advanced or Metastatic Gastrointestinal Cancers Exploring Treatment Combinations With Pelareorep and Atezolizumab (PHASE1, PHASE2)
- A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer) (PHASE1, PHASE2)
- BMS-813160 With Nivolumab and Gemcitabine and Nab-paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC) (PHASE1, PHASE2)
- Safety Study of Radio-labeled huA33 Antibody in Colorectal Cancer (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 5% Albumin infusion 3 hours CI brief — competitive landscape report
- 5% Albumin infusion 3 hours updates RSS · CI watch RSS
- Region Skane portfolio CI